Nerdy Analysts Cut Their Forecasts After Weak Forecast

Nerdy, Inc. (NYSE: NRDY) reported upbeat results for its third quarter, but issued a weak forecast.

Nerdy, Inc. (NYSE:NRDY) reported upbeat results for its third quarter, but issued a weak forecast.

Nerdy posted quarterly loss of 13 cents per share, compared to market expectations for a loss of 21 cents per share. The company’s quarterly sales came in at $40.30 million versus estimates of $39.04 million.

Nerdy said it sees fourth-quarter revenue of $54 million to $56M million versus analysts’ estimates of $60.92 million. The company expects FY23 revenue of $192 million to $194 million versus estimates of $198.02 million.

Nerdy shares fell 19.2% to trade at $2.5050 on Wednesday.

These analysts made changes to their price targets on Nerdy following earnings announcement.

  • Raymond James slashed the price target on Nerdy from $5.5 to $4. Raymond James analyst Alexander Sklar maintained an Outperform rating.
  • Cantor Fitzgerald cut the price target on Nerdy from $8 to $6. Cantor Fitzgerald analyst Brett Knoblauch maintained an Overweight rating.

Now Read This: Disney Gears Up For Q4 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Total
0
Shares
Related Posts
Read More

AstraZeneca, Swedish Orphan Biovitrum And Sanofi Have Updated And Simplified Their Contractual Arrangements Relating To The Development And Commercialization Of Nirsevimab In The US

AstraZeneca, Swedish Orphan Biovitrum AB (publ) (Sobi) and Sanofi have updated and simplified their contractual arrangements relating to the development and commercialisation of nirsevimab in the US. Given the upcoming launch of nirsevimab in the US and other markets, simplification of the prior arrangements clarifies the roles and responsibilities of relevant parties.   

AZN